ARNOLD FRANCES 4

What Happened
Frances Arnold, a director of Generate Biomedicines (GENB), received a grant of 29,561 derivative securities on Feb 26, 2026. The filing reports an acquisition price of $0.00 (total reported $0). The award is listed as a derivative grant (transaction code A) and is not an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-26; Form 4 filed: 2026-03-02 (appears later than the usual 2-business-day filing window).
• Amount: 29,561 derivative shares/options reported at $0.00 (total reported $0).
• Shares owned after transaction: Not specified in the filing.
• Footnote: The shares underlying this option shall vest in full on February 19, 2027, subject to Arnold’s continued service on that date.
• Transaction code: A (grant/award/other acquisition); derivative securities (not an immediate sale).

Context
This was an equity award to a director that vests in full about one year after the grant; until vesting, Arnold does not beneficially own vested shares. Awards to directors are routine compensation and do not necessarily signal immediate buying or selling activity. The later filing date may be a reporting delay—common but worth noting for transparency.